disease 650 words KG: ent-dise-bc979601 2026-03-24
kind:diseasesection:diseasesstate:published
Contents

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Disease Info
Prevalence1-2 per 100,000 population
Age of onsetCan occur at any age, most commonly in adults aged 40-60
Gender distributionSlight male predominance (M:F = 1.5:1)
CourseVariable—some patients have monophasic illness, others have relapsing-remitting or progressive pattern
Progressive weaknessArms and legs, typically symmetric
Sensory lossNumbness, particularly in hands and feet
Loss of deep tendon reflexesDiminished or absent
Difficulty walkingGait disturbance
FatigueGeneralized fatigue
PainParticularly in back and legs
Balance problemsDue to sensory and motor impairment
Typical CIDPClassic presentation with symmetric proximal and distal weakness
DatabasesOMIMOrphanetClinicalTrialsPubMed

Knowledge Graph

Related Hypotheses (2)

Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu
Score: 0.57

Related Analyses (6)

What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · archived
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Microglial subtypes in neurodegeneration — friend vs foe
neuroscience · failed

Related Experiments (15)

Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Macroautophagy Dysfunction in PD - Experiment Design
clinical · proposed · Score: 0.40
Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40